Key Outcome of HCV Trial: BIT225 Was Safe and Well-Tolerated
Biotron Phase 2 Hepatitis C Trial Success
March 17, 2016
PRNewswire — Biotron Limited (ASX: BIT) confirms positive outcomes from its Phase 2 study of its first-in-class antiviral drug BIT225.
The trial was designed to assess the safety and antiviral activity of three month’s dosing of BIT225 in patients infected with Hepatitis C virus (HCV). In addition, the trial provided key information on a new capsule form of BIT225, information that is critical for determining dosage in further studies with the drug.
Continue reading this entire article: